Unexplained weight loss, medically termed as 'involuntary weight loss' (IWL), is a common yet perplexing clinical scenario that often poses significant diagnostic challenges. It is defined as a loss of more than 5% of body weight over a period of 6 to 12 months without an apparent cause. This article aims to provide a comprehensive approach to evaluating unexplained weight loss in clinical practice.
The initial assessment should involve a thorough history and physical examination, focusing on dietary intake, physical activity, psychological status, and medication use. The presence of associated symptoms such as anorexia, dysphagia, or gastrointestinal symptoms may provide clues to the underlying cause.
Basic laboratory investigations should include a complete blood count, basic metabolic panel, liver function tests, thyroid function tests, and inflammatory markers. If initial tests are unremarkable, further investigations such as endoscopy, imaging studies, or specialized blood tests may be warranted based on clinical suspicion.
Imaging studies play a crucial role in evaluating unexplained weight loss. Abdominal ultrasound, CT scan, or MRI may be used to identify potential malignancies, chronic infections, or metabolic disorders. PET scan may be considered in patients with high suspicion of malignancy but negative initial workup.
The management of unexplained weight loss is directed at the underlying cause. In cases where no cause is identified, a symptom-focused approach may be adopted, including nutritional support and psychological intervention.
In conclusion, unexplained weight loss is a complex clinical entity requiring a systematic and comprehensive approach for evaluation. The aim should be to identify treatable causes and to provide supportive care in cases where no underlying cause can be found. Further research is needed to develop more effective diagnostic algorithms and management strategies for this challenging clinical scenario.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation